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Abstract: The pandemic associated to Severe Acute Respiratory Syndrome Coronavirus type 2
(SARS-CoV-2) has resulted in a huge number of deaths and infected people. Although several
vaccine programmes are currently underway and have reached phase 3, and a few small size drugs
repurposed to aid treatment of severe cases of COVID-19 infections, eective therapeutic options
for this disease do not currently exist. NSP16 is a S-adenosyl-L-Methionine (SAM) dependent
20O-Methyltransferase that converts mRNA cap-0 into cap-1 structure to prevent virus detection by
cell innate immunity mechanisms. NSP16 methylates the ribose 20O-position of the first nucleotide of
the mRNA only in the presence of an interacting partner, the protein NSP10. This feature suggests
that inhibition of the NSP16 may represent a therapeutic window to treat COVID-19. To test this idea,
we performed comparative structural analyses of the NSP16 present in human coronaviruses and
developed a sinefungin (SFG) similarity-based virtual screening campaign to assess the druggability
of the SARS-CoV-2 NSP16 enzyme. Through these studies, we identified the SFG analogue 44601604
as a promising more potent inhibitor of NSP16 to limit viral replication in infected cells, favouring
viral clearance.
Keywords: SARS-CoV-2; drug target; NSP16/NSP10; 20O-Methyltransferase inhibition; virtual screening
1. Introduction
There is urgency to develop eective therapeutics against the SARS-CoV-2, the causing agent of the
ongoing COVID-19 pandemic. There are seven types of human Coronavirus (CoVs): 229E, NL63, OC43,
HKU1, Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome type
1 (SARS-CoV) and SARS-CoV-2. SARS-CoV-2 has a high amino acid sequence homology to human
betacoronavirus SARS-CoV and MERS and a much lower conservation with other coronaviruses.
SARS-CoV-2 is proved to be highly pathogenic and cause severe lung injury and multi-organ failure.
Currently, there is no vaccine approved to treat COVID-19. However, a few small size drugs originally
developed to treat other diseases, such as remdesivir, which was initially developed for hepatitis C but
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proved to be ineective, have been repurposed as an aid to treat severe cases of COVID-19. Although
an earlier clinical trial in China (February/March 2020) showed that remdesivir was not eective in
reducing deaths or the time for improvement from COVID-19 and caused various adverse eects,
resulting in the early termination of the trial, remdesivir has been approved in the European Union
for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental
oxygen [1].
SARS-CoV-2 contains a single positive stranded-RNA genome of approximately 29,800 bases which
encodes four structural proteins—Spike (S) glycoprotein, small Envelope (E) glycoprotein, Membrane
(M) glycoprotein, and Nucleocapsid (N)—and sixteen non-structural proteins (NSP1–NSP16) that
play important roles in virus transcription and replication [2–5] (Figure 1). The distinctive feature of
eukaryotic mRNAs is characterised by the presence of a methylated 50-cap structure that is required for
mRNA stability. Viruses that infect eukaryotic organisms generally modify the 50-cap of viral RNAs to
mimic the hosts mRNA structure. In this manner, the virus protects itself from degradation by 50-30
exoribonucleases, enables ecient translation and escapes recognition by the host immune system.
SARS-CoV-2 encodes one SAM-dependent methyltransferase (a 20O-MTase also known as NSP16)
that methylates the RNA cap at ribose 20O positions. Importantly, this enzyme is only active in the
presence of its activating partner, the non-structural protein NSP10. The formation of the NSP16/NSP10
complex, which follows a 1:1 stoichiometry ratio, has only been identified in coronaviruses. Crystal
structures of the NSP16/NSP10 heterodimer in complex with the co-substrate and methyl donor
SAM (Figure 2) (Protein Data Bank (PDB) IDs 6W4H, 6W61, 6W75 and 7C2J) [6]; with the reaction
subproduct S-Adenosyl-L-Homocysteine (SAH) (Figure 2) (PDB ID 6WJT); with the inhibitor SFG
(Figure 2) (PDB IDs 6WKQ and 6YZ1); in complex with RNA substrate (GTA) and SAM (PDB IDs 6WKS
and 6WVN); and with GTA and SAH (PDB ID 6WQ3) have been reported over the years (Table S1
and Figure 1), providing important insight into the enzyme’s catalysis mechanism and its mode of
interaction with small size ligands [7,8]. Interestingly, NSP16 can methylate GTA (mGpppA-RNA)
but not GTG (mGpppG-RNA) substrates. One conserved groove region of the enzyme is essential
for mRNA binding and defined by KDKE residues. Amino acid residue substitutions of the KDKE
residues of NSP16 attenuate virus infection in vitro and in vivo.
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In the present study, we initiated a virtual screening campaign on the SARS-CoV-2
methyltransferase NSP16, a 20O-MTase with critical roles in viral replication and anti-viral immune
response. In brief, we identified the key residues of NSP16 that are required for mRNA and cofactor
binding and, therefore, for the regulation of 20O-MTase catalytic activity (Table S1). Our virtual
screening of SARS-CoV-2 NSP16 using a crystal structure of the NSP16/NSP10 complex (PDB ID 6YZ1)
enabled us to rank the predicted binding anities around the cofactor-binding site and identify 4
top hit compounds corresponding to 18 drugs that exhibit high chemical similarity with the NSP16
inhibitor SFG. Our studies confirm the high potential of targeting SARS-CoV-2 NSP16 catalytic activity
with small size inhibitors to treat COVID-19 infections.
2. Results
2.1. Comparative Analysis and Structural Characterisation of 20O-MTase from Coronavirus
Similar to other coronavirus, SARS-CoV-2 replicates in the cytoplasm of infected cells, enabling
it to produce its own capping machinery. Its 20O MTase enzyme, commonly referred to NSP16, in
complex with the non-structural protein NSP10 catalyses the formation of viral mRNA cap structures
that mimic those present in the host mRNAs [9]. The cap structure consists of a methylated guanosine
at position 7 linked to the first transcribed nucleotide by a 50-50 triphosphate bridge (7mGpppN). The
cap structure plays several key roles in mRNA functionality such as pre-mRNA processing, nuclear
export and cap-dependent protein synthesis [10]. The cap structure is also essential for mRNA stability
and limits its degradation by cellular 50-30 exoribonucleases. Structural similarity analysis of analogues
of the natural NSP16 co-substrate SAM suggest that SAM-analogue compounds that act as competitive
binders of SAM may be potent inhibitors of 20O-MTase catalytic activity.
The human betacoronavirus SARS-CoV-2 shares a high amino acid sequence similarity to human
betacoronaviruses SARS-CoV and MERS (Figure 3). The high SARS-CoV, MERS CoV and SARS-CoV-2
sequence similarity is reflected in their pathogenicity to the human, causing influenza-like symptoms
that range from mild discomfort to severe lung injury and multi-organ failure, eventually leading
to death.
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Figure 3. Sequence alignment of 20O-MTases (e.g., NSP16) viral proteins from SARS-CoV-2, SARS-CoV
and MERS-CoV. Residues that are fully conserved are shown in solid black boxes; those with identity
of 70% or higher are shown in white boxes. The secondary structure of SARS-CoV-2 NSP16 derived
from the crystal structure (PDB ID 6WKQ) is shown above the alignments. Figure generated with the
program ESPript 3.0 [11].
2.1.1. NSP16 is a Suitable Drug Target
Several crystal structures of NSP16 SARS-CoV-2 have been solved recently and the coordinates
deposited in the PDB. These include NSP16 in complex with SAM (PDB IDs 6W4H, 6W61, 6W75
an 7C2J), with SAH (PDB ID 6WJT), with SFG (PDB IDs 6WKQ and 6YZ1), with SAM and RNA
(PDB IDs 6WKS and 6WVN) and with SAH and RNA (PDB ID 6WQ3). SAH is the by-product of
SAM-dependent methyl transfer reaction, whereas SFG is a SAM analogue that functions as a SAM
competitive i hibi or (Table S1). The structures rev led that NSP16 adopts th catechol O-MT e fold
containing alter ating  strands (1–7) and  h lic s (Z and A–E) that form a seven-stranded 
sheet with three  he ices on each side (Figure 1). Our analysis of these crystal structures confirmed
that SAM, SAH and SFG bind to a well-d fined pocket in NSP16, which is not surprising giv n the
very slight variations of the chemical structure of these smal molecules (Figure 4). SAM contains
an additional sulphur atom in comparis t SAH, and, for SFG compared with SAM and SAH, a
nitrogen substitutes the sulphur atoms. RNA binds t a reg on that is in close proximity to the SAM
binding pocket with a orientation that allows its ribose ring to become close proximity to he amin
group of the SAM cofactor, which is required for the NSP16-dependant 20O methylat on of th RNA
substrate (Figure 4). Moreover, the RNA structure does not seem to be alt red upon SAM, SAH and
SFG binding. Reciprocally, the mode of binding of these thr e molecules to NPS16 does not dier in
the abs nce or presence of RNA.
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Figure 4. SAM-dependent methyltransferases (MTases) ligands and RNA in complex with SARS-CoV-2
NSP16: (A) surface representation of the NSP16 (teal), SAM (yellow) and RNA (green) ternary complex;
and (B) surface representation of NSP16 (teal), SAH (magenta) and RNA (green) ternary complex.
The deposited atomic coordinates of SARS-CoV-2 NSP16 crystal structures prompted us
to investigate the structural similarities of this enzyme with a human cap-specific mRNA
(nucleoside-20O-)-MTase (PDB ID 4N48). Our analysis revealed two highly conserved elements.
One is the SAM binding pocket, which defines the relative orientation of the methyl group donor.
The other conserved element consists of the residues that define the enzyme active site (Figure 5).
Interestingly, although the NPS16 cap-binding site can be mapped onto a similar region in SARS and
MERS coronavirus, human and viral 20O-ribose mRNA MTases interact with the guanosine cap very
dierently (Figure 6). The substantial dierence in the overall topology of human and viral 20O-ribose
mRNA MTases strongly suggests that the latter can be specifically targeted with small molecules that
occupy the SAM binding site. In this regard, it would be important to assess whether small-molecule
antagonists of SAM binding to NSP16 of SARS-CoV-2 may be repurposed to limit viral replication
and/or unmask viral RNA to the host immune system.
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Figure 5. apping the residues i plicated in SA and RNA binding onto the SARS-CoV-2 NSP16
structure. (A) Surface representation of SARS-CoV-2 NSP16 (teal) (PDB ID 6WKS) showing the relative
positions of the SAM (yellow) and RNA (green) binding regions. The RNA molecule binds to a groove
proximal to the SAM binding pocket. The NSP16 residues located within 4 Å of SAM and RNA
are shown in deep salmon and purple colour, respectively. (B) Ribbon representation of the ternary
complex in the same orientation as (A).
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2.1.2. NSP16 Exhibits a Druggable Pocket
The first crystal structures of the non-structural protein NSP16 from SARS-CoV-2 revealed a
well-defined co-substrate binding pocket. More recently, the crystal structure of NSP16 SARS-CoV-2 in
complex with the small size compound SFG was solved and the coordinates deposited in the PDB
(IDs 6WKQ and 6YZ1) (Figure 7). As 20O-methylation of viral RNA cap structures limited the infected
host’s antiviral respo se, small size compounds that interfere with NSP16 20O-MTase catalytic activity
are likely to undergo viral cleara ce in the infected lls.
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Figure 7. Crystal structure of SARS-CoV-2 NSP16 complexes. (A) NSP16 in complex with the inhibitor
SFG. The inhibitor (shown in orange) binds to the same region as SAM ( DB ID 6WKQ). (B) S ructure
superposition of SARS-CoV-2 NSP16 in complex with SAM (yellow) and RNA (green) (PDB ID 6WVN)
with that of NSP16 in complex with SFG, a SAM analogue in which an amino group substitutes the
sulphur atom of the former. The structure superposition shows that SAM and SFG bind to the same
NSP16 pocket and that RNA binding implicates a region proximal to the SAM binding pocket.
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2.2. Virtual Screening
Herein, we aimed to identify novel NSP16 inhibitors based on the SFG chemotype. For this purpose,
we developed a High-Throughput Virtual Screening (HTVS) using the recently solved structure of the
NSP10-NSP16 complex bound to the MTase inhibitor SFG (PDB ID 6YZ1) in an attempt to identify
novel drug-like molecules with improved NSP16 binding and optimised pharmacokinetics profile.
A chemical library of compounds sharing >0.85 Tanimoto similarity index with SFG and complying
Lipinski’s rules was retrieved from PubChem [12]. This database of 1321 molecules was used as
the input source for our HTVS upon ligand preparation. The LigPrep module integrated in the
Maestro software was used to optimise chemical structure conformations considering the most suitable
ionisation state under physiological pH conditions and possible tautomers. This process allowed
us to obtain low-energy molecules minimised using the OPLS3 force field [13]. It is worth noting
that the Tanimoto similarity is calculated between a reference active molecule structure (commonly
referred to as fingerprint) and multiple query fingerprints. Although, in principle, using a (>0.85)
cut-o for the Tanimoto similarity measurement may lead to the exclusion of possible candidates
with good 3D similarity to SFG, the use of the Schrödinger molecular modelling suite reduced this
risk. This is because the Schrödinger modelling suite incorporates a minimised Structural Interaction
Fingerprint (SIFt) approach that was originally developed by Deng and collaborators [14]. The SIFt
integrated in Maestro (Schrödinger, LLC, New York, NY, 2019) includes nine interaction types (any
contact, backbone contact, sidechain contact, polar contact, hydrophobic contact, H-bond donor and
acceptor, aromatic and charged interactions).
This library of compounds was then subjected to molecular docking studies using the HTVS
Glide-dock module integrated in the Schrödinger package [15,16]. High precision docking calculations
using XP Glide (Schrödinger, LLC, New York, NY, 2019) were accomplished for the compounds with
the highest docking scores in the HTVS. Selected candidates are shown in Figure 8, and their XP Glide
interaction energies are displayed in Table 1. SFG was included in our studies to allow energetic
comparison (the binding pose in which SFG conformation matches the crystallographic structure was
selected, Figure S1). Docks of the most promising candidates are shown in Figure 9. Ligand interaction
diagrams and the dock of 44367977 superimposed to SFG are shown in Figures S2 and S3. These
docks show that, while maintaining the crucial interactions exhibited by the adenosine moiety of SFG,
structural diversity of the alkyl chain is not only accepted but it even improves the predicted energy of
complex formation.
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QPlogS a QlogBB b QPlogKp c QPlogKhsa d Docking Score e 
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71008334 0.45 −1.41 −9.96 −0.81 −11.81 
14728195 0.45 −1.86 −9.77 −0.92 −11.66 
25200440 0.34 −1.96 −9.67 −0.90 −11.63 
66856272 0.17 −1.68 −9.27 −0.91 −11.57 
44601596 −0.48 −2.52 −8.14 −1.29 −11.50 
44601604 −1.32 −2.00 −7.62 −1.16 −11.42 
66855668 0.36 −1.54 −9.39 −0.91 −11.04 
57126779 −0.96 −2.71 −8.96 −0.94 −11.00 
54016655 −1.51 −1.53 −6.63 −0.67 −10.83 
57324736 −0.02 −1.92 −9.82 −0.89 −10.11 
117805851 −0.87 −1.70 −7.80 −0.78 −10.06 
91397803 −0.76 −2.26 −8.43 −0.92 −9.95 
71444955 −0.99 −2.60 −7.69 −1.08 −9.94 
SFG −0.39 −3.17 −11.50 −1.29 −8.09 
a Predicted aqueous solubility [–6.5/0.5]; b predicted log of the brain/blood partition coefficient 
[−3.0/1.2]; c predicted skin permeability, log Kp [−8.0/−1.0]; d predicted binding to human serum 
albumin [–1.5/1.5]; [range of 95% of drugs]; e XP GScore (Kcal/mol). 
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Table 1. Physicochemical descriptors of selected compounds from the HTVS computed with QikProp
and Glide docking score.
Compound (PubChem ID) QPlogS a QlogBB b QPlogKp c QPlogKhsa d Docking Score e
44367977 0.20  1.82  9.60  0.99  12.05
25203154 .33  1.56  9.04  0.94  11.83
71008334 .45  1.41  9.96  0.81  11.81
14728195  1.86  9.77  0.92  11.66
25200440 34  1.96  9.67  0.90  11.63
66856 72 17  1.68  9.27  0.91  11.57
4460159  0.48  2.52  8.14  1.29  11.50
44601 4  1.32  2.00  7.62  1.16  11.42
66855 68 0. 6  1.54  9.39  0.91  11.04
5712 779  0.96  2.71  8.96  0.94  11.00
54016655  1.51  1.53  6.63  0.67  10.83
5732 73  0.02  1.92  9.82  0.89  10.11
117805851   .87  1.70  7.80  0.78  10.06
91397 3   .76  2.26  8.43  0.92  9.95
71444955   .99  2.60  7.69  1.08  9.94
SFG   .39  3.17  11.50  1.29  8.09
a Predicted aqueous solubility [ 6.5/0.5]; b predicted log of the brain/blood partition coecient [ 3.0/1.2]; c predicted
skin permeability, log Kp [ 8.0/ 1.0]; d predicted bin ng to human serum albumin [ 1.5/1.5]; [range o 95% of
drugs]; e XP GScore (Kcal/mol).
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Figure 9. NSP16-ligand complexes generated using our molecular docking strategy: (A)
44367977/NSP16; (B) 25203154/NSP16; (C) 71008334/NSP16; and (D) 44601604/NSP16. Yellow dashed
lines represent hydrogen bonds, magenta dashed lines represent salt bridges and blue dashed lines
show aromatic stacking; non-polar hydrogens are not shown. Direct interacting residues are displayed
as grey tubes; the ligand chemical backbone is shown in orange with oxygen atoms highlighted in red
and nitrogen atoms in blue.
The novel molecules demonstrate that the aminoacidic part of SFG or SAM can be substituted
by a simple aminoalkyl chain to improve the number of stabilising interactions with NSP16.
Conformationally restricted groups such as pyrrolidine, borne by 44601604, are also accepted in
the pocket with an improved docking score when compared to SFG. As shown in Figure 9A–D, an
additi al salt bridge between th amin at position 2 of the alkyl chain (44367977 and 25203154),
the amine of the pentose moiety (71008334) and the pyrrolidine nitrogen (44601604) and the NSP16
residue D99, as well as an extra hydrogen bond with the backbone carbonyl oxygen of NSP16
residue G73, can all contribute to stabilise the NSP16–drug-like compound complexes, resulting in
improved docking energies when compared to SFG. It is worth noting that the terminal carboxylic
acid group of SFG, SAM or SAH is not present in the alkyl chain of most of the top-ranking molecules.
However, losing the hydrogen bond between the carboxylate and the NSP16 residue N43 (Figure S1) is
energetically compensated by the aforementioned stabilising interactions. Concerning the pentose
moiety, modification of the tetrahydrofuran group including an amino (71008334), a thiol (54016655)
or the absence of substituent (140671722) at positions 3 or 4 are all predicted to be tolerated. One of
the two hydroxyls is retained in all the best candidate hits. No substantial conformational changes
were identified in the adenine group of the top-ranking molecules. Therefore, our results indicate
the versatility of the amino acidic-like chain of SFG, whereas the nucleoside moiety seems to highly
stabilise the complex. It is worth remarking that molecules with higher docking scores are dicationic
(Table 1). This is likely the result of both cations engaging in stabilising polar interactions with the two
negatively charged residues facing the binding site (D99 and D130, Figure 9), thus contributing to the
global binding energy of the complex.
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In the search of eective SARS-CoV-2 NSP16 inhibitors, it is crucial to avoid the presence of
potential promiscuous moieties or Pan-Assay Interference compounds (PAINS) [17,18]. Therefore, the
selected molecules were subjected to a PAINS identification study using the swissADME webserver [19].
Compounds 144802777, 25245977 and 140671722 bear potential liabilities (a sulfonium ion) and therefore
were filtered out during compound selection. Moreover, in silico prediction of properties related
to Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) were calculated using
the QikProp screening tool of Maestro (Schrödinger, LLC, New York, NY, 2019). Our drug-likeness
calculations indicate that the molecules identified as potent NSP16 inhibitors abide to the Lipinski and
Jorgensen pharmacokinetic rules [20,21]. As depicted in Table 1, the prediction of aqueous solubility,
blood–brain barrier permeability, or binding to human serum albumin suggest that these candidates
have a suitable drug profile. Predicted skin permeability values of some of the candidates fall outside
the range predicted by QikProp for 95% of known oral drugs. However, they present better values
than SFG. It is worth noting that the analogue 44601604 (Figure 9D) is the most promising candidate
since it exhibits the best theoretical energy value of complex-formation and presents an optimal
pharmacokinetics profile.
It is worth mentioning that, while SFG has already been widely studied, no biological activity for
most of the identified compounds has been reported (Table S2). PubChem BioAssays for 44601596 and
44601604 showed either inactive or inconclusive results. This may allow the identification of more
selective and ecacious hit compounds. Even though the best candidates obtained from our virtual
screening shared similar main cores with SFG, a wider structural diversity was also explored, which led
to lower score compounds that diverge at the adenine group position. Future work will aim to explore
further structural diversity, including the systematic bioisosteric replacement of the molecular scaold.
3. Discussion
Current eorts around the globe to treat COVID-19, the disease caused by the coronavirus
SARS-CoV-2, are focused in the production of vaccines and small size drugs. On the one hand, vaccine
development eorts are concentrated in the four main structural proteins: Spike (S) glycoprotein, small
Envelope (E) glycoprotein, Membrane (M) glycoprotein and Nucleocapsid (N) protein. Although
some vaccine development programmes have successfully completed phase 2 clinical trials, whether a
SARS-CoV-2 vaccine will be able to elicit long-term immunity in the human population, regardless
of specific ethnicity, gender and/or age group, remains to be seen. On the other hand, independent
clinical trials around the world have shown that some drugs originally approved for their use in the
human to treat a dierent disease condition, can be repurposed to aid the treatment of severe cases of
COVID-19 infection that required hospitalisation and the use of mechanical respirators. Hence, the
use of small size drugs arises as an important therapeutic strategy to treat COVID-19. Building on
this knowledge, we developed a chemoinformatics campaign focused on the non-structural protein
NSP16, an enzyme that presents 20O-MTase activity and plays a key role in 20O-methylation of viral
RNA cap structures to limit the antiviral response of the host’s infected cells. Through this in silico
study, SFG derivatives with a more potent and druggable profile than SFG were identified as potential
NSP16 SARS-CoV-2 inhibitors. Top ranking derivatives bind to a well-defined pocket of the enzyme
exhibiting the importance of specific residues of this cleft to establish a productive interaction with the
small size ligands. The chemical space in the vicinity of the aminoacidic moiety of SFG was widely
explored. It was noted that the most potent compounds preserve the adenosine core, thus confirming
its relevance for the establishment of productive interactions with NSP16. The exploitation of these
features will pave the way to design further broad-spectrum inhibitors that could not only target
SARS-CoV-2 NSP16 but also the orthologue proteins found in other coronaviruses. For instance, the
addition of a keto group at the appropriate position of the pyrrolidine ring of compound 44601604
should enable a further stabilising interaction with the NSP16 residue N43. Future work will aim at
fine-tuning our chemical scaold to design molecules that while maintaining desirable pharmacological
features can also be extended to occupy the binding crevice.
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4. Materials and Methods
4.1. Virtual Screening
The 20O-MTase structure file from Protein Data Bank (PDB ID 6YZ1) was used in our modelling
studies [22]. Initial protein optimisation was accomplished using the Protein Preparation Wizard
module integrated in the Maestro suite software (Schrödinger, LLC, New York, NY, USA, 2019).
4.1.1. Ligand Preparation
A chemical library was downloaded from PubChem using the SFG chemotype as the lead structure.
This PubChem dataset consists of 1321 compounds that comply the following criteria: Tanimoto
similarity index >0.85 to SFG and no violation of Lipinsky’s rules for drug likeness [12]. The selected
cut-o value of the Tanimoto coecient enables the simultaneous optimisation of the SFG chemotype
and the exploration of novel functional substitutions.
Low-energy three-dimensional conformations of the molecules were obtained using the LigPrep
module of the Maestro suite (Schrödinger, LLC, New York, NY, USA, 2019). Additionally, the Epik
software was employed to predict pKa values in the pH range between 7.0 and 7.5 and return all
chemically sensible structures using Hammett and Taft methodology [23]. All compounds were
minimised using the OPLS3 force field as implemented in Maestro [13].
4.1.2. High-Throughput Virtual Screening (HTVS)
Molecular docking was performed using the HTVS Glide-dock module integrated in the
Schrödinger package [15,16]. The aforementioned chemical library of 1321 unique structures
(considering diverse low energy conformers for each molecule) was explored in the binding site
of our target 20O-MTase. The docking grid was built using Glide and was centred on the position of
the crystallised inhibitor, SFG, setting the dimensions of 20 Å. Ligand flexibility was used to explore an
arbitrary number of torsional degrees of freedom, in addition to the six spatial degrees of freedom
spanned by the translational and rotational parameters. Ligand poses generated in such a way were
run through a series of hierarchical filters to evaluate ligand interactions with the receptor. Docking
score, glide gscore, glide emodel, ionisation penalty and Topological Polar Surface Area (TPSA) were
used to select the docking poses [15,16]. Molecules with docking scores lower than  10 Kcal/mol were
selected for further docking studies. High precision docking calculations using the XP Glide were
performed with the best candidates (18 molecules, Figure 8) and the lead compound SFG, which was
included to allow comparison. Energy minimisation was performed using the OPLS3 force field 4.1.3
ADMET in silico calculations.
The SwissADME [19] server was used to evaluate the presence of promiscuous moieties in the
selected candidates. Molecules 144802777, 25245977 and 140671722 were filtered o due to presence of
a sulfonium ion, identified as PAINS, in their structure. The ADME/Tox profiles of the remaining 15
molecules identified by the HTVS were further explored. For this purpose, a set of 34 physicochemical
descriptors was computed using QikProp version 3.5 integrated in Maestro (Schrödinger, LLC, New
York, NY, USA). The QikProp descriptors are depicted in Table 1.
5. Conclusions
Using a similarity-based virtual screening approach, we propose the use of certain SFG analogues
as SARS-CoV-2 NSP16 inhibitors. Best ranking molecules not only present improved docking energies
but also better druggable pharmacokinetic profiles compared to the well-known pan 20O-MTase
inhibitor sinefungin (SFG). We anticipate that some of these compounds can be developed into
therapeutic drugs against SARS-CoV-2 by limiting viral replication in the infected cells. Inhibition of
the viral 20O-MTase activity might stimulate the detection of viral RNAs by the host RIG-I or Mda5
antiviral pathway and restore the host antiviral response mediated by interferon-stimulated proteins
that recognise mis-capped RNA and inhibit its translation. It is our hope that the present study on the
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identification and chemoinformatics characterisation of SARS-CoV-2 NPS16 MTase drug-like binders
will stimulate others to join the global eorts to advance the development of molecules to tackle the
pandemic COVID-19 disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4344/10/9/1023/s1.
Table S1, IDs of the 3D-structure of the 20O-methyltransferases; Figure S1, Molecular docking of SFG in NSP16;
Figure S2, The 44367977/NSP16 complex with SFG superimposed; Figure S3, Ligand interaction diagrams of SFG,
44367977, 25203154, 71008334 and 44601604; Table S2, PubChem indexed biological assays results for the identified
molecules and SFG.
Author Contributions: Conceptualisation, V.M.B.-G. and A.B.; methodology, P.M. and N.L.C.; software, P.M. and
S.G.Z.; resources, S.G.Z.; writing—review and editing, P.M., N.L.C., S.G.Z., A.B. and V.M.B.-G.; and supervision,
V.M.B.-G. and A.B. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by CSIC (CSIC-COV19-013) and MICINN (PID2019-105337RB-C21).
Acknowledgments: P.M. is grateful to the Comunidad de Madrid program “Atracción de Talento” number
2018-T2BMD-10819. N.L.C. is supported by a Professor Nigel Groome PhD Studentship, Oxford Brookes University.
We thank the anonymous referees for their insightful and helpful comments and suggestions. We apologise to
those colleagues whose important contributions to this field could not be cited due to space limitations.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. European Medicines Agency. First COVID-19 treatment recommended for EU authorisation. In European
Medicines Agency EMA/264817; European Medicines Agency: Amsterdam, The Netherlands, 2020; pp. 1–2.
2. Gorbalenya, A.E.; Baker, S.C.; Baric, R.S.; de Groot, R.J.; Drosten, C.; Gulyaeva, A.A.; Haagmans, B.L.;
Lauber, C.; Leontovich, A.M.; Neuman, B.W.; et al. The species Severe acute respiratory syndrome-related
coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020, 5, 536–544.
3. Perlman, S.; Netland, J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat. Rev.
Microbiol. 2009, 7, 439–450. [CrossRef]
4. Wu, A.; Peng, Y.; Huang, B.; Ding, X.; Wang, X.; Niu, P.; Meng, J.; Zhu, Z.; Zhang, Z.; Wang, J.; et al. Genome
Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe
2020, 27, 325–328. [CrossRef]
5. Snijder, E.J.; Decroly, E.; Ziebuhr, J. The Nonstructural Proteins Directing Coronavirus RNA Synthesis and
Processing. Adv. Virus Res. 2016, 96, 59–126. [PubMed]
6. Chen, Y.; Su, C.; Ke, M.; Jin, X.; Xu, L.; Zhang, Z.; Wu, A.; Sun, Y.; Yang, Z.; Tien, P.; et al. Biochemical and
structural insights into the mechanisms of sars coronavirus RNA ribose 20-O-methylation by nsp16/nsp10
protein complex. PLoS Pathog. 2011, 7, e1002294. [CrossRef] [PubMed]
7. Decroly, E.; Debarnot, C.; Ferron, F.; Bouvet, M.; Coutard, B.; Imbert, I.; Gluais, L.; Papageorgiou, N.;
Shar, A.; Bricogne, G.; et al. Crystal structure and functional analysis of the SARS-coronavirus RNA cap
20-o-methyltransferase nsp10/nsp16 complex. PLoS Pathog. 2011, 7, e1002059. [CrossRef]
8. Rosas-Lemus, M.; Minasov, G.; Shuvalova, L.; Inniss, N.; Brunzelle, J.; Satchell, K.J.F. Structure of SARS-CoV-2
20-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for
structure-based inhibitor design. Bio Rxiv 2020, 1–26.
9. Hyde, J.L.; Diamond, M.S. Innate immune restriction and antagonism of viral RNA lacking 20-O methylation.
Virology 2015, 479–480, 66–74. [CrossRef]
10. Ramanathan, A.; Robb, G.B.; Chan, S.H. mRNA capping: Biological functions and applications. Nucleic Acids
Res. 2016, 44, 7511–7526. [CrossRef]
11. Robert, X.; Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic
Acids Res. 2014, 42, 320–324. [CrossRef]
12. Kim, S.; Thiessen, P.A.; Bolton, E.E.; Chen, J.; Fu, G.; Gindulyte, A.; Han, L.; He, J.; He, S.; Shoemaker, B.A.;
et al. PubChem substance and compound databases. Nucleic Acids Res. 2016, 44, D1202–D1213. [CrossRef]
[PubMed]
13. Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J.Y.; Wang, L.; Lupyan, D.; Dahlgren, M.K.;
Knight, J.L.; et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and
Proteins. J. Chem. Theory Comput. 2016, 12, 281–296. [CrossRef]
Catalysts 2020, 10, 1023 13 of 13
14. Deng, Z.; Chuaqui, C.; Singh, J. Structural Interaction Fingerprint (SIFt): A Novel Method for Analyzing
Three-Dimensional Protein-Ligand Binding Interactions. J. Med. Chem. 2004, 47, 337–344. [CrossRef]
[PubMed]
15. Warren, G.L.; Andrews, C.W.; Capelli, A.M.; Clarke, B.; LaLonde, J.; Lambert, M.H.; Lindvall, M.; Nevins, N.;
Semus, S.F.; Senger, S.; et al. A critical assessment of docking programs and scoring functions. J. Med. Chem.
2006, 49, 5912–5931. [CrossRef] [PubMed]
16. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.;
Mainz, D.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for
protein-ligand complexes. J. Med. Chem. 2006, 49, 6177–6196. [CrossRef]
17. Capuzzi, S.J.; Muratov, E.N.; Tropsha, A. Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay
Interference Compounds. J. Chem. Inf. Model. 2017, 57, 417–427. [CrossRef]
18. Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS)
from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53, 2719–2740. [CrossRef]
19. Daina, A.O.M.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and
medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [CrossRef]
20. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol.
Toxicol. Methods 2001, 44, 235–249. [CrossRef]
21. Jorgensen, W.L.; Duy, E.M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev. 2002, 54,
355–366. [CrossRef]
22. Krafcikova, P.; Silhan, J.; Nencka, R.; Boura, E. Structural analysis of the SARS-CoV-2 methyltransferase
complex involved in coronaviral RNA cap creation. Bio Rxiv 2020, 11, 1–7.
23. Greenwood, J.R.; Calkins, D.; Sullivan, A.P.; Shelley, J.C. Towards the comprehensive, rapid, and accurate
prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J. Comput. Aided.
Mol. Des. 2010, 24, 591–604. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
